Jimmy,
Thank you. Clear, concise and on the money. Leronlimab is not the problem. It has immense promise, but establishing a cashflow is a big speedbump.
An especially interesting comment on your part - Brazil, which is going through its own hell with the virus, is coming into fall and then winter which theoretically will intensify their plight. I hope they avail themselves of leronlimab.
Unfortunately, thank you Janet, we will NOT have access to Leronlimab until God knows when (I guess the FDA must have a compendium entitled "Clever Special Delaying Tactics For Annoying Small Biotechs" an entire chapter devoted to requiring Receptor Occupancy followed by numerous other Chapters and strategies). It's startling how many more people will suffer, and expire needlessly while Janet "fiddles and diddles."
News 
Market Data 
Discover 
AI
